Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 9/20 | 0.41 |
| ▸ | CDK8 | P49336 | 9/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10138424 | 0.96 | CCNC (0.41) | CCNCCDK8FFAR4MAPK1GRM2 | |
| SCHEMBL10138449 | 0.94 | CCNC (0.40) | CCNCCDK8FFAR4MAPK1GRM2 | |
| SCHEMBL10138499 | 0.88 | CCNC (0.43) | CCNCCDK8FFAR4GRM2PDE4A | |
| SCHEMBL10138435 | 0.86 | CCNC (0.41) | CCNCCDK8MAPK1GRM2ALOX5AP | |
| SCHEMBL10138415 | 0.84 | CCNC (0.52) | CCNCCDK8GRM2ALOX5APFEN1 | |
| SCHEMBL14823068 | 0.82 | CCNC (0.41) | CCNCCDK8FFAR4GRM2PDE4A | |
| SCHEMBL10138476 | 0.81 | CCNC (0.42) | CCNCCDK8MAPK1ALOX5APFEN1 | |
| SCHEMBL578375 | 0.81 | CCNC (0.48) | CCNCCDK8CYP11B2 | |
| SCHEMBL10138453 | 0.81 | CCNC (0.41) | CCNCCDK8GRM2ALOX5APFEN1 | |
| SCHEMBL10138521 | 0.81 | CCNC (0.41) | CCNCCDK8GRM2PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | BMP2, BMP4, BMP6 | CCNC 1592/4885CDK8 2959/4885FFAR4 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.